Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

Get full text

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS by Amy E. DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, Jose-Miguel Torregrossa-Diaz, Giovanni Marconi, Teresa Bernal, Juan Bergua Burgues, Blanca Xicoy, Anna Jonášová, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcarcel, Maria Diez Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz Basak, Hetty E. Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A. Roth, Sofia Paul, Pourab Roy, Michael J. Kelly, Angela Volkert, Jaime Chisholm, Tanya Abdul Malak, Virginia M. Klimek, Thomas Cluzeau

Get full text